Nebivolol (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic blocker used in the management of arterial hypertension and related cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
• Primary hypertension: improves vascular tone and reduces peripheral resistance.
• Essential hypertension: helps prevent long‑term cardiovascular complications associated with high blood pressure.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, which together reduce peripheral vascular resistance and lower systemic blood pressure.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness.
• Nausea or mild gastrointestinal upset.
• Bradycardia: heart rate slower than normal.
• Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension with risk of syncope.
• Bronchospasm or worsening asthma symptoms.
• Allergic reactions such as rash, pruritus, or angioedema.
• Hepatic dysfunction or elevated liver enzymes.
• Acute heart failure decompensation.

When prescribing or dispensing Nebivolol, consider the following safety measures.

• Blood pressure monitoring: regularly assess to ensure therapeutic control.
• Heart rate assessment: watch for excessive bradycardia.
• Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction.
• Discontinuation: avoid abrupt cessation; taper under medical supervision.
• Renal or hepatic impairment: dose adjustment may be required.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects.
• Calcium‑channel blockers (e.g., verapamil, diltiazem): may cause profound bradycardia or AV block.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect.

• ACE inhibitors or ARBs: combined use can lead to excessive blood pressure lowering.
• NSAIDs: may reduce antihypertensive efficacy.
• Antiarrhythmic agents (e.g., amiodarone): potential for conduction disturbances.
• Antidiabetic drugs: monitor glucose as beta‑blockade may mask hypoglycaemia symptoms.